baclofen has been researched along with Alcohol Drinking in 97 studies
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this." | 9.27 | Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018) |
| " The present study evaluated the effect of the combination of the opioid receptor antagonist, naltrexone, with the GABA(B) receptor agonist, baclofen, on the acquisition of alcohol drinking behavior in Sardinian alcohol-preferring (sP) rats." | 7.73 | Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats. ( Carai, MA; Colombo, G; Gessa, GL; Serra, S; Vacca, G, 2005) |
| " Baclofen safety was evaluated by adverse reaction occurrence during treatment." | 7.01 | Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases. ( Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023) |
| " HDB induces frequent neuropsychiatric adverse events (AEs)." | 5.42 | Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015) |
| "Baclofen is a promising drug for treating patients with alcohol-related disorders." | 5.34 | Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. ( Jaury, P; Le Jeunne, C; Perrodeau, E; Porcher, R; Rigal, L; Sidorkiewicz, S; Tréluyer, JM, 2020) |
| "Data from a randomised controlled trial (RCT) (N = 104), in which AUD patients received placebo or baclofen (30 mg/day or 75 mg/day) for 12 weeks, were analysed to determine predictive effects of the following four clinical characteristics: alcoholic liver disease (ALD), baseline alcohol consumption, craving and anxiety." | 5.30 | Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. ( Baillie, A; Haber, PS; Morley, KC; Rombouts, SA, 2019) |
| "Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this." | 5.27 | Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018) |
| " Baclofen has been shown to promote abstinence, to reduce craving, and to reduce anxiety in alcohol-dependent individuals, and it promises to be a useful agent, although clinical data are limited at present." | 5.24 | Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. ( Arora, S; Elwadhi, D; Gupta, M; Rastogi, R; Verma, P, 2017) |
| " Different lines of evidence indicate that direct agonists, including baclofen, effectively suppress acquisition and maintenance of alcohol drinking behavior, relapse-like drinking, and alcohol's reinforcing, rewarding, stimulating, and motivational properties in rats and mice." | 4.85 | Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. ( Colombo, G; Maccioni, P, 2009) |
| "These results are in close agreement with those of a preliminary clinical study and suggest that baclofen may constitute a novel therapeutic agent for alcoholism." | 3.70 | Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. ( Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Lobina, C; Pani, M; Reali, R, 2000) |
| "Baclofen daily dose was 30 mg to 300 mg: 10 RCTs used low doses (30 mg or less); eight RCTs medium doses (above 30 and 100 mg or less) and four RCTs high doses (above 100 mg)." | 3.01 | Baclofen for alcohol use disorder. ( Agabio, R; Minozzi, S; Rösner, S; Saulle, R, 2023) |
| " Baclofen safety was evaluated by adverse reaction occurrence during treatment." | 3.01 | Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases. ( Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023) |
| "Baclofen has been suggested as a potential pharmacotherapy for alcohol use disorder, but the clinical data are conflicting." | 2.84 | Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. ( Amodio, JP; Bollinger, JW; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Lionetti, TA; Schwandt, ML; Sewell, L; Spero, DE, 2017) |
| "Alcohol dependence is a major public health issue with a need for new pharmacological treatments." | 2.84 | A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. ( Aubin, HJ; Dano, C; Dematteis, M; Detilleux, M; Paille, F; Reynaud, M; Trinquet, F; Trojak, B; Zakine, B, 2017) |
| " Clinical efficacy was assessed by Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWA-Ar) and tolerability by the nature and severity of adverse events." | 2.82 | A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. ( Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016) |
| "Depression was assessed with Montgomery-Ashberg scale." | 2.80 | [Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence]. ( Alexeeva, YV; Berntsev, VA; Chekhlaty, EI; Kiselev, AS; Krupitsky, EM; Neznanov, NG; Popov, YV; Rybakova, KV; Zubova, EY, 2015) |
| "Effective treatments for alcohol use disorders in those with significant liver disease are critically lacking." | 2.78 | The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. ( Baillie, A; Haber, PS; Leung, S; Morley, KC, 2013) |
| " Baclofen was well tolerated with only 2 individuals stopping baclofen because of adverse events." | 2.75 | Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. ( Flannery, BA; Gallop, R; Garbutt, JC; Kalka-Juhl, L; Kampov-Polevoy, AB, 2010) |
| " With the background that individualized, rather than fixed, high dosing with baclofen could be critical for success, a large (n = 320), industry-independent, 62-center French RCT (the Bacloville trial) examined whether individually uptitrated, high-dose baclofen could reduce alcohol consumption in heavy drinkers across a year of treatment." | 2.66 | Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption. ( Andrade, C, 2020) |
| "Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment." | 2.58 | Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. ( Jones, A; Rose, AK, 2018) |
| "Participants had a diagnosis of alcohol dependence according the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or the International Classification of Diseases (ICD)-10 criteria who were currently drinking." | 2.58 | Baclofen for alcohol use disorder. ( Minozzi, S; Rösner, S; Saulle, R, 2018) |
| " However, HDB has been associated with numerous reports of adverse events (AEs)." | 2.53 | Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. ( Auffret, M; Franchitto, N; Rolland, B, 2016) |
| "Alcohol use disorders are common, but only a small minority of patients receive adequate treatment." | 2.52 | Recent Developments in Pharmacotherapy of Alcoholism. ( Lieb, M; Soyka, M, 2015) |
| "Baclofen has been tested for its capacity to reduce craving for alcohol." | 2.49 | Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013. ( , 2013) |
| " Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis." | 2.46 | Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. ( Addolorato, G; Leggio, L, 2010) |
| "Treatment with baclofen also suppressed the number of daily drinks and decreased the obsessive and compulsive components of alcohol craving." | 2.42 | Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. ( Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Pibiri, F; Serra, S; Vacca, G, 2004) |
| "7%) were still receiving baclofen at a mean dosage of 75 mg/day (r30-210)." | 1.91 | Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study. ( Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023) |
| "Baclofen has been trialled for AUD in cirrhosis and appears to be effective." | 1.72 | Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. ( Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022) |
| "R(+)-Baclofen was more effective than RS(±)-Baclofen in reducing ethanol intake and seeking during acute withdrawal and during relapse after abstinence." | 1.62 | Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side. ( Bloch, V; Echeverry-Alzate, V; Jeanblanc, J; Labat, L; Naassila, M; Sauton, P; Soichot, M; Vorspan, F, 2021) |
| "Medical management of alcohol use disorders." | 1.51 | [Medical management of alcohol use disorders]. ( Paille, F, 2019) |
| "Baclofen has been shown to reduce alcohol consumption in alcohol-dependent individuals, but there is marked heterogeneity in response." | 1.48 | Moderation of baclofen response by a GABA ( Baillie, A; Dore, G; Fraser, I; Haber, PS; Luquin, N; Morley, KC; Phung, N; Trent, RJ, 2018) |
| "Diazepam 20 mg was used up to three times per day, but didn't seem to improve or reduce the anxiety, agitation, visual or auditory hallucinations." | 1.48 | Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence. ( Calvo, ME; Gunnarsson, T; Hao, M; Smith, L, 2018) |
| " At a mean dosage of 40 mg/day (extremes: 30-210), the median daily alcohol consumption reduced from 80 to 0 g/day (P<0." | 1.46 | One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. ( Barrault, C; Béhar, V; Cadranel, JF; Costentin, C; Garioud, A; Hagège, H; Lison, H; Medmoun, M; Pulwermacher, G; Roudot-Thoraval, F, 2017) |
| "Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year." | 1.46 | The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Duhamel, A; Gautier, S; Labreuche, J; Pignon, B; Rolland, B; Simioni, N, 2017) |
| "Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD)." | 1.46 | Speaking fluently with baclofen? ( Beraha, E; Bodewits, P; van den Brink, W; Wiers, R, 2017) |
| "Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed." | 1.46 | Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. ( Auffret, M; Baguet, A; Bordet, R; Cabe, N; Carton, L; Cottencin, O; Deheul, S; Dervaux, A; Dib, M; Drelon, M; Duhamel, A; Gautier, S; Grit, I; Guillin, O; Jardri, R; Kemkem, A; Labreuche, J; Lapeyre-Mestre, M; Masquelier, C; Rolland, B; Vabret, F, 2017) |
| " Further randomized studies alongside investigation of dosing strategies are required." | 1.46 | A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. ( Gilmore, I; Owens, L; Pirmohamed, M; Richardson, P; Rose, A; Thompson, A, 2017) |
| " HDB induces frequent neuropsychiatric adverse events (AEs)." | 1.42 | Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015) |
| "Baclofen is a γ-aminobutyric acid B (GABA-B) receptor agonist that is approved for spasticity." | 1.40 | Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. ( Bence, C; Bordet, R; Carton, L; Cottencin, O; Deheul, S; Jaillette, E; Rolland, B; Saulnier, F, 2014) |
| "Alcohol dependence is associated with a wide array of physical and psychiatric complications and is a major cause of morbidity and mortality worldwide." | 1.38 | High-dose baclofen for treatment-resistant alcohol dependence. ( Currie, J; Jones, DM; Pastor, A, 2012) |
| "Baclofen alone has minimal abuse liability in heavy social drinkers, and baclofen is relatively well tolerated and safe when given in combination with intoxicating doses of alcohol." | 1.35 | Acute interaction of baclofen in combination with alcohol in heavy social drinkers. ( Bisaga, A; Evans, SM, 2009) |
| "Baclofen or saline was microinjected into the anterior or posterior VTA of male C57BL/6J mice." | 1.35 | Site-specific microinjection of baclofen into the anterior ventral tegmental area reduces binge-like ethanol intake in male C57BL/6J mice. ( Boehm, SL; Moore, EM, 2009) |
| "Pretreatment with baclofen, which failed to alter alcohol intake when given alone, dose-dependently suppressed morphine- and WIN 55,212-2-induced promotion of alcohol drinking." | 1.32 | Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. ( Carai, MA; Colombo, G; Gessa, GL; Serra, S; Vacca, G, 2004) |
| "5 mg/kg), a GABAB agonist, administered alone or in combination with a single dose of naltrexone (1." | 1.32 | The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. ( Stromberg, MF, 2004) |
| "Baclofen was orally administered for 4 weeks, at a dose of 15 mg/day refracted in three times per day for the first 3 days, with the dose increased to 30 mg/day for the remaining 27 days." | 1.31 | Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. ( Addolorato, G; Capristo, E; Caputo, F; Colombo, G; Gasbarrini, G; Gessa, GL, 2000) |
| "Baclofen-treated animals then were observed to consume greater amounts of ethanol than did saline controls throughout the remainder of the dark cycle as well as into the light cycle." | 1.30 | The effects of the GABA(B) agonist baclofen on the temporal and structural characteristics of ethanol intake. ( Amit, Z; Boyle, AE; Smith, BR, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.09) | 18.2507 |
| 2000's | 22 (22.68) | 29.6817 |
| 2010's | 50 (51.55) | 24.3611 |
| 2020's | 22 (22.68) | 2.80 |
| Authors | Studies |
|---|---|
| Maccioni, P | 7 |
| Lorrai, I | 2 |
| Carai, MAM | 1 |
| Gessa, GL | 14 |
| Colombo, G | 15 |
| Bach, P | 1 |
| Tyson, LD | 2 |
| Cheng, A | 1 |
| Kelleher, C | 1 |
| Strathie, K | 1 |
| Lovendoski, J | 1 |
| Habtemariam, Z | 1 |
| Lewis, H | 2 |
| Giri, S | 1 |
| Sundaram, S | 1 |
| Bauer, MR | 1 |
| Hernández, M | 1 |
| Kasten, CR | 1 |
| Boehm, SL | 2 |
| Logge, W | 1 |
| Baillie, A | 4 |
| Haber, P | 1 |
| Towers, E | 1 |
| Riordan, BC | 1 |
| Morley, K | 1 |
| Barrault, C | 3 |
| Alqallaf, S | 2 |
| Lison, H | 3 |
| Lamote-Chaouche, I | 2 |
| Bourcier, V | 2 |
| Laugier, J | 2 |
| Thevenot, T | 2 |
| Labarriere, D | 2 |
| Ripault, MP | 2 |
| Le Gruyer, A | 2 |
| Costentin, C | 3 |
| Behar, V | 3 |
| Hagege, H | 3 |
| Jung, C | 2 |
| Cadranel, JF | 3 |
| Agabio, R | 6 |
| Saulle, R | 2 |
| Rösner, S | 2 |
| Minozzi, S | 2 |
| Ross, H | 1 |
| Harries, B | 1 |
| Szelest, I | 1 |
| Engelbrecht, R | 1 |
| Umhau, JC | 1 |
| Price, ST | 1 |
| Brown, B | 1 |
| Duan, F | 1 |
| Zhai, H | 1 |
| Liu, C | 1 |
| Chang, C | 1 |
| Song, S | 1 |
| Li, J | 1 |
| Cheng, J | 1 |
| Yang, S | 1 |
| Rigal, L | 2 |
| Sidorkiewicz, S | 2 |
| Tréluyer, JM | 1 |
| Perrodeau, E | 1 |
| Le Jeunne, C | 2 |
| Porcher, R | 2 |
| Jaury, P | 2 |
| Echeverry-Alzate, V | 1 |
| Jeanblanc, J | 1 |
| Sauton, P | 1 |
| Bloch, V | 2 |
| Labat, L | 1 |
| Soichot, M | 1 |
| Vorspan, F | 2 |
| Naassila, M | 1 |
| Paille, F | 2 |
| Naudet, F | 3 |
| Braillon, A | 3 |
| Cristea, IA | 1 |
| Lexchin, J | 1 |
| Andrade, C | 2 |
| Minnaard, AM | 1 |
| Ramakers, GMJ | 1 |
| Vanderschuren, LJMJ | 1 |
| Lesscher, HMB | 1 |
| Baldwin, DS | 1 |
| Amaro, H | 1 |
| Leggio, L | 7 |
| Sinclair, JMA | 1 |
| Engrand, N | 1 |
| Roy-Gash, F | 1 |
| Bouvier, D | 1 |
| Dinkelacker, V | 1 |
| Farokhnia, M | 1 |
| Schwandt, ML | 1 |
| Lee, MR | 1 |
| Bollinger, JW | 1 |
| Farinelli, LA | 1 |
| Amodio, JP | 1 |
| Sewell, L | 1 |
| Lionetti, TA | 1 |
| Spero, DE | 1 |
| Beraha, E | 1 |
| Bodewits, P | 1 |
| van den Brink, W | 1 |
| Wiers, R | 1 |
| Pignon, B | 2 |
| Labreuche, J | 3 |
| Auffret, M | 5 |
| Gautier, S | 4 |
| Deheul, S | 5 |
| Simioni, N | 1 |
| Cottencin, O | 5 |
| Bordet, R | 5 |
| Duhamel, A | 3 |
| Rolland, B | 6 |
| Reynaud, M | 1 |
| Aubin, HJ | 1 |
| Trinquet, F | 1 |
| Zakine, B | 1 |
| Dano, C | 1 |
| Dematteis, M | 1 |
| Trojak, B | 1 |
| Detilleux, M | 1 |
| Roudot-Thoraval, F | 1 |
| Garioud, A | 1 |
| Medmoun, M | 1 |
| Pulwermacher, G | 1 |
| Holtyn, AF | 1 |
| Kaminski, BJ | 2 |
| Weerts, EM | 2 |
| Owens, L | 1 |
| Thompson, A | 1 |
| Rose, A | 1 |
| Gilmore, I | 1 |
| Pirmohamed, M | 1 |
| Richardson, P | 1 |
| Contini, A | 1 |
| Leite-Morris, K | 1 |
| Boels, D | 1 |
| Victorri-Vigneau, C | 1 |
| Grall-Bronnec, M | 1 |
| Touré, A | 1 |
| Brunet, M | 1 |
| Hamel, JF | 1 |
| Le Roux, G | 1 |
| Martinez, L | 1 |
| Declèves, X | 1 |
| Azuar, J | 1 |
| Fortias, M | 1 |
| Questel, F | 1 |
| Dereux, A | 1 |
| Grichy, L | 1 |
| Barreteau, H | 1 |
| Bellivier, F | 1 |
| Lépine, JP | 1 |
| Donoghue, K | 1 |
| Rose, AK | 1 |
| Jones, A | 1 |
| Bianchi, PC | 1 |
| Carneiro de Oliveira, PE | 1 |
| Palombo, P | 1 |
| Leão, RM | 1 |
| Cogo-Moreira, H | 1 |
| Planeta, CDS | 1 |
| Cruz, FC | 1 |
| Beraha, EM | 1 |
| Salemink, E | 1 |
| Krediet, E | 1 |
| Wiers, RW | 1 |
| Morley, KC | 3 |
| Luquin, N | 1 |
| Fraser, I | 1 |
| Trent, RJ | 1 |
| Dore, G | 1 |
| Phung, N | 1 |
| Haber, PS | 3 |
| Calvo, ME | 1 |
| Gunnarsson, T | 1 |
| Smith, L | 1 |
| Hao, M | 1 |
| Rombouts, SA | 1 |
| Khoo, SY | 1 |
| Sciascia, JM | 1 |
| Pettorelli, A | 1 |
| Maddux, JN | 1 |
| Chaudhri, N | 1 |
| Leung, S | 1 |
| Jaillette, E | 1 |
| Carton, L | 2 |
| Bence, C | 1 |
| Saulnier, F | 1 |
| Wilden, JA | 1 |
| Qing, KY | 1 |
| Hauser, SR | 1 |
| McBride, WJ | 1 |
| Irazoqui, PP | 1 |
| Rodd, ZA | 1 |
| Zywiak, WH | 2 |
| Edwards, SM | 1 |
| Tidey, JW | 1 |
| Swift, RM | 4 |
| Kenna, GA | 4 |
| Peana, AT | 1 |
| Muggironi, G | 1 |
| Spina, L | 1 |
| Rosas, M | 1 |
| Kasture, SB | 1 |
| Cotti, E | 1 |
| Acquas, E | 1 |
| Valin, T | 2 |
| Langlois, C | 1 |
| Danel, T | 1 |
| Vargiolu, D | 1 |
| Thomas, AW | 1 |
| Malherbe, P | 1 |
| Mugnaini, C | 2 |
| Corelli, F | 2 |
| Leite-Morris, KA | 1 |
| Soyka, M | 1 |
| Lieb, M | 1 |
| Krupitsky, EM | 1 |
| Rybakova, KV | 1 |
| Kiselev, AS | 1 |
| Alexeeva, YV | 1 |
| Berntsev, VA | 1 |
| Chekhlaty, EI | 1 |
| Zubova, EY | 1 |
| Popov, YV | 1 |
| Neznanov, NG | 1 |
| Franchitto, N | 1 |
| Girish, K | 1 |
| Vikram Reddy, K | 1 |
| Pandit, LV | 1 |
| Pundarikaksha, HP | 1 |
| Vijendra, R | 1 |
| Vasundara, K | 1 |
| Manjunatha, R | 1 |
| Nagraj, M | 1 |
| Shruthi, R | 1 |
| Gupta, M | 1 |
| Verma, P | 1 |
| Rastogi, R | 1 |
| Arora, S | 1 |
| Elwadhi, D | 1 |
| Lapeyre-Mestre, M | 1 |
| Dib, M | 1 |
| Kemkem, A | 1 |
| Grit, I | 1 |
| Drelon, M | 1 |
| Cabe, N | 1 |
| Vabret, F | 1 |
| Guillin, O | 1 |
| Baguet, A | 1 |
| Masquelier, C | 1 |
| Dervaux, A | 1 |
| Jardri, R | 1 |
| Ferrulli, A | 2 |
| Cardone, S | 2 |
| Malandrino, N | 2 |
| Mirijello, A | 1 |
| D'Angelo, C | 1 |
| Vonghia, L | 1 |
| Miceli, A | 2 |
| Capristo, E | 3 |
| Gasbarrini, G | 2 |
| Addolorato, G | 9 |
| Evans, SM | 1 |
| Bisaga, A | 1 |
| Garbutt, JC | 2 |
| Moore, EM | 1 |
| Kampov-Polevoy, AB | 1 |
| Gallop, R | 1 |
| Kalka-Juhl, L | 1 |
| Flannery, BA | 1 |
| Tanchuck, MA | 1 |
| Yoneyama, N | 1 |
| Ford, MM | 1 |
| Fretwell, AM | 1 |
| Finn, DA | 1 |
| Amini, M | 1 |
| Runyon, BA | 1 |
| Nesci, A | 1 |
| Canestrelli, B | 1 |
| Monteleone, P | 1 |
| Dean, RL | 1 |
| Eyerman, D | 1 |
| Todtenkopf, MS | 1 |
| Turncliff, RZ | 1 |
| Bidlack, JM | 1 |
| Deaver, DR | 1 |
| Pastor, A | 1 |
| Jones, DM | 1 |
| Currie, J | 1 |
| Duke, AN | 1 |
| Zaru, A | 1 |
| Loi, B | 1 |
| Lobina, C | 2 |
| Carai, MA | 10 |
| Capra, A | 1 |
| Pasquini, S | 1 |
| Hyytiä, P | 1 |
| Lumeng, L | 1 |
| Villas Boas, GR | 1 |
| Zamboni, CG | 1 |
| Peretti, MC | 1 |
| Correia, D | 1 |
| Rueda, AV | 1 |
| Camarini, R | 1 |
| Brunialti-Godard, AL | 1 |
| Boerngen-Lacerda, R | 1 |
| Peters, S | 1 |
| Slattery, DA | 1 |
| Flor, PJ | 1 |
| Neumann, ID | 1 |
| Reber, SO | 1 |
| McGeary, JE | 1 |
| Edwards, S | 1 |
| Fricchione, SR | 1 |
| Shoaff, JR | 1 |
| Vacca, G | 6 |
| Serra, S | 6 |
| Brunetti, G | 1 |
| Anstrom, KK | 1 |
| Cromwell, HC | 1 |
| Markowski, T | 1 |
| Woodward, DJ | 1 |
| Janak, PH | 1 |
| Michael Gill, T | 1 |
| Stromberg, MF | 1 |
| Pibiri, F | 2 |
| Castelli, MP | 1 |
| Piras, AP | 1 |
| Carboni, G | 1 |
| Orrù, A | 2 |
| Pes, D | 1 |
| Liang, JH | 1 |
| Chen, F | 1 |
| Krstew, E | 1 |
| Cowen, MS | 1 |
| Carroll, FY | 1 |
| Crawford, D | 1 |
| Beart, PM | 1 |
| Lawrence, AJ | 1 |
| Knapp, DJ | 1 |
| Overstreet, DH | 1 |
| Breese, GR | 1 |
| Marras, P | 1 |
| Carpiniello, B | 1 |
| Bienkowski, P | 1 |
| Smith, BR | 2 |
| Boyle, AE | 1 |
| Amit, Z | 2 |
| Pani, M | 1 |
| Reali, R | 1 |
| Caputo, F | 1 |
| Robidoux, J | 1 |
| Allan, AM | 1 |
| Burnett, D | 1 |
| Harris, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics[NCT01751386] | Phase 2 | 39 participants (Actual) | Interventional | 2012-12-03 | Completed | ||
| Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease[NCT01711125] | Phase 3 | 104 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking[NCT01076283] | Phase 2 | 14 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Effect of Omega-5 Fatty Acid Supplement on Markers of Inflammation and Oxidative Stress in Patients With Severe Alcoholic Hepatitis Treated With Prednisone[NCT03732586] | 40 participants (Actual) | Interventional | 2018-09-30 | Completed | |||
| Effects of Ghrelin on Alcohol Cue Reactivity and Craving[NCT01190085] | 45 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| A Novel Compound for Alcoholism Treatment: A Translational Strategy[NCT02039349] | Phase 1 | 14 participants (Actual) | Interventional | 2014-01-03 | Completed | ||
| Effects of Ghrelin on Alcohol Administration in Non-Treatment Seeking Heavy Drinkers[NCT01779024] | Phase 2 | 17 participants (Actual) | Interventional | 2012-12-13 | Completed | ||
| Treating Alcohol Withdrawal With Oral Baclofen: a Randomized, Double Blind, Placebo Controlled Trial[NCT00597701] | 79 participants (Actual) | Interventional | 2003-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL. (NCT01751386)
Timeframe: 2 hours
| Intervention | mini-drinks (Mean) |
|---|---|
| Baclofen | 4.11 |
| Placebo | 4.5 |
"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration
| Intervention | standard drinking units (Mean) |
|---|---|
| Baclofen | 0.17 |
| Cyproheptadine | 1.43 |
"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration
| Intervention | units on a scale (Mean) |
|---|---|
| Baclofen | 22.5 |
| Cyproheptadine | 19.4 |
"Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Visual Analogue Scale (A-VAS)].~The A-VAS was rated on 11-point anchored Likert-type scales, where 0 is the minimum score (no craving) and 11 is the maximum score (highest craving intensity). The change in the A-VAS score (deltaA-VAS) was used to indicate decrease (-d) or increase (+d) in craving intensity." (NCT01190085)
Timeframe: approximately 30 minutes after drug administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ghrelin (1 Microg/kg) | 1.95 |
| Ghrelin (3 Microg/kg) | 2.66 |
| Saline Solution | 4.29 |
Whether ghrelin intravenous (i.v.), as compared to saline i.v., does not significantly increase Adverse Events (AEs). (NCT01190085)
Timeframe: participants will be followed after the cue-reactivity experiment, an expected average of 7 days
| Intervention | participants (Number) |
|---|---|
| Ghrelin (1 Microg/kg) | 11 |
| Ghrelin (3 Microg/kg) | 12 |
| Saline Solution | 15 |
Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of psychophysiological responses, namely salivation changes. (NCT01190085)
Timeframe: approximately 30 minutes after drug administration
| Intervention | gram (Mean) |
|---|---|
| Ghrelin (1 Microg/kg) | 1.8 |
| Ghrelin (3 Microg/kg) | 1.9 |
| Saline Solution | 3.2 |
The total number of alcohol infusions self-administered. (NCT01779024)
Timeframe: 120 minutes after the start of the infusion
| Intervention | Number of alcohol infusions (Mean) |
|---|---|
| Ghrelin | 10.45 |
| Placebo | 8.80 |
In acutely-withdrawing alcoholic patients treated with either baclofen or placebo, symptom-driven benzodiazepine doses were assessed for the 72 hours following the first Clinical Institute Withdrawal Assessment (CIWA) score of 11 or greater. (NCT00597701)
Timeframe: From eligibility for randomization (Clinical Institute Withdrawal Assessment [CIWA] score of at least 11) until 72 hours of observation had been completed.
| Intervention | mg of benzodiazepine per 8 hours (Mean) |
|---|---|
| Baclofen | 14.1 |
| Placebo | 124.4 |
15 reviews available for baclofen and Alcohol Drinking
| Article | Year |
|---|---|
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans | 2022 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; M | 2023 |
Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Craving; Humans; Liver Diseases | 2023 |
Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption.
Topics: Alcohol Drinking; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Meta-Analysis as Topic | 2020 |
The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Humans | 2021 |
Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.
Topics: Affect; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Depression; GA | 2018 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Craving; Depression; Female | 2018 |
Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2013 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Na | 2015 |
Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment.
Topics: Alcohol Drinking; Alcoholism; Algorithms; Baclofen; Dose-Response Relationship, Drug; GABA-B Recepto | 2016 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations | 2009 |
Role of the GABA(B) receptor in alcohol-seeking and drinking behavior.
Topics: Alcohol Drinking; Alcoholism; Allosteric Regulation; Animals; Baclofen; Cyclopentanes; GABA Modulato | 2009 |
Safety and efficacy of baclofen in the treatment of alcohol-dependent patients.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Re | 2010 |
Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy.
Topics: Alcohol Deterrents; Alcohol Drinking; Anti-Inflammatory Agents; Baclofen; Combined Modality Therapy; | 2010 |
Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Clinical Trials as Topic; Ethanol; GABA Agonists; H | 2004 |
14 trials available for baclofen and Alcohol Drinking
| Article | Year |
|---|---|
Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time during baclofen treatment for alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Craving; Female; Humans; Male; Sex Characteristics | 2023 |
Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Baclofen; Double-Blind Method; Female; Follow-Up | 2020 |
Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Biobehavioral Sciences; Craving; Double-Blin | 2017 |
A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Craving; Double-Blind Method; Female; GABA-B Receptor | 2017 |
Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Anxiety Disorders; Attentional Bias; | 2018 |
Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Dose-Response Rel | 2019 |
The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Clinical Protocols; Double-Blind Method; Drug Administration | 2013 |
A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2015 |
[Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence].
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind M | 2015 |
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Topics: Adult; Alcohol Drinking; Baclofen; Chlordiazepoxide; Diazepam; Humans; Lorazepam; Male; Middle Aged; | 2016 |
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; GABA-B Receptor | 2017 |
Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind Method; | 2010 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
68 other studies available for baclofen and Alcohol Drinking
| Article | Year |
|---|---|
Blockade of the GABAB receptor suppressed alcohol self-administration in rats: an effect similar to that produced by GABAB receptor activation.
Topics: Alcohol Drinking; Animals; Baclofen; Behavior, Animal; Dose-Response Relationship, Drug; GABA-B Rece | 2022 |
Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Retrospective Studies | 2022 |
Acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Systemic administration of racemic baclofen reduces both acquisition and maintenance of alcohol consumption in male and female mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Ethanol; Female; GABA-B Receptor Agonists; Male; Mi | 2022 |
Response to 'acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?'
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Incorporating ondansetron and baclofen in alcohol use disorder treatment.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Ondansetron | 2023 |
Baclofen for the Treatment of Alcohol Use Disorder.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans | 2023 |
Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor A | 2021 |
[Medical management of alcohol use disorders].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Humans | 2019 |
Restoring the Bacloville trial: efficacy and harms.
Topics: Alcohol Drinking; Baclofen; Follow-Up Studies; GABA-B Receptor Agonists; Humans; Outpatients | 2020 |
Reply to comments on the Rigal et al. (2019) Bacloville trial.
Topics: Alcohol Drinking; Baclofen; Follow-Up Studies; Humans; Outpatients | 2020 |
Baclofen and naltrexone, but not N-acetylcysteine, affect voluntary alcohol drinking in rats regardless of individual levels of alcohol intake.
Topics: Acetylcysteine; Alcohol Drinking; Animals; Baclofen; Ethanol; GABA-B Receptor Agonists; Male; Naltre | 2021 |
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit.
Topics: Alcohol Drinking; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans | 2021 |
Dr Andrade Replies.
Topics: Alcohol Drinking; Baclofen; Humans | 2021 |
Effect of high-dose baclofen on agitation-related events among patients with unhealthy alcohol use receiving mechanical ventilation: Plea for a pharmacodynamic monitoring, the EEG.
Topics: Alcohol Drinking; Baclofen; Electroencephalography; Humans; Intensive Care Units; Respiration, Artif | 2021 |
Speaking fluently with baclofen?
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Human | 2017 |
The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Dose-Response Relationship, Drug; | 2017 |
Baclofen and alcohol use disorders: From miracle to mirage.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans | 2017 |
One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Female; France; GABA-B Receptor A | 2017 |
Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Baclofen; Disease Models, Animal; GABA-B | 2017 |
A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic.
Topics: Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Bilirubin; Biomarkers; Coho | 2017 |
Microinjection of baclofen and CGP7930 into the ventral tegmental area suppresses alcohol self-administration in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Central Nervous System Depressants; Dose-Response Relationship, | 2018 |
Response to the Letter to the Editor Regarding "Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning."
Topics: Alcohol Drinking; Alcoholism; Baclofen; Ethanol; Humans; Risk | 2018 |
An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Baclofen; Diazepam; Female; GABA Modulato | 2018 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Netwo | 2018 |
Functional inactivation of the orbitofrontal cortex disrupts context-induced reinstatement of alcohol seeking in rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Conditioning, Operant; Drug-Seeking Behavior; Femal | 2018 |
Moderation of baclofen response by a GABA
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male; Middl | 2018 |
Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Diazepam; H | 2018 |
The medial prefrontal cortex is required for responding to alcohol-predictive cues but only in the absence of alcohol delivery.
Topics: Alcohol Drinking; Animals; Baclofen; Conditioning, Operant; Cues; Drug-Seeking Behavior; Ethanol; Ex | 2019 |
KASL clinical practice guidelines: management of alcoholic liver disease.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Baclofen; Disulfiram; Fatty Liver, | 2013 |
Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Conf | 2014 |
Reduced ethanol consumption by alcohol-preferring (P) rats following pharmacological silencing and deep brain stimulation of the nucleus accumbens shell.
Topics: Alcohol Drinking; Animals; Baclofen; Conditioning, Operant; Deep Brain Stimulation; Ethanol; Female; | 2014 |
Effects of Withania somnifera on oral ethanol self-administration in rats.
Topics: Administration, Oral; Alcohol Drinking; Animals; Baclofen; Conditioning, Operant; Dose-Response Rela | 2014 |
Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Borderline Personality Disorder; | 2015 |
Inhibition of alcohol self-administration by positive allosteric modulators of the GABAB receptor in rats: lack of tolerance and potentiation of baclofen.
Topics: Alcohol Drinking; Allosteric Regulation; Animals; Baclofen; Benzofurans; Cyclopentanes; Drug Synergi | 2015 |
High-dose baclofen: withdrawal syndrome following abrupt discontinuation.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Drug Administration Schedule; GABA-B Rec | 2014 |
Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Central Nervous System Depressants; Dose | 2015 |
Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
Topics: Alcohol Drinking; Alcoholism; Algorithms; Baclofen; Cohort Studies; Drug Monitoring; Follow-Up Studi | 2017 |
Relationship between the hypothalamic-pituitary-thyroid axis and alcohol craving in alcohol-dependent patients: a longitudinal study.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Behavior, Addictive; Female; Humans; Hypothalamo-Hypo | 2008 |
Acute interaction of baclofen in combination with alcohol in heavy social drinkers.
Topics: Adult; Alcohol Drinking; Baclofen; Breath Tests; Double-Blind Method; Drug Interactions; Ethanol; Fe | 2009 |
Site-specific microinjection of baclofen into the anterior ventral tegmental area reduces binge-like ethanol intake in male C57BL/6J mice.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Baclofen; Catheterization; Circadian Rhythm; Darkne | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism | 2009 |
Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking.
Topics: Alcohol Drinking; Animals; Baclofen; Disease Models, Animal; Ethanol; Excitatory Amino Acid Antagoni | 2011 |
Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.
Topics: Administration, Oral; Alcohol Deterrents; Alcohol Drinking; Animals; Animals, Outbred Strains; Baclo | 2012 |
High-dose baclofen for treatment-resistant alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Female; GABA-B Rece | 2012 |
Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons.
Topics: Adult; Alcohol Drinking; Analysis of Variance; Animals; Baclofen; Conditioning, Operant; Cues; Disea | 2014 |
Comparison of the effect of the GABAΒ receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats.
Topics: Alcohol Drinking; Allosteric Regulation; Animals; Baclofen; Cyclopentanes; Ethanol; GABA Modulators; | 2012 |
GABA(B) receptor agonist only reduces ethanol drinking in light-drinking mice.
Topics: Alcohol Drinking; Animals; Baclofen; Body Weight; Dose-Response Relationship, Drug; Drinking Behavio | 2012 |
Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Baclofen; Disease Models, A | 2013 |
Baclofen suppresses motivation to consume alcohol in rats.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Baclofen; Conditioning, Operant; Disease Models, An | 2003 |
Effect of baclofen on alcohol and sucrose self-administration in rats.
Topics: Alcohol Drinking; Animals; Baclofen; Conditioning, Operant; Dose-Response Relationship, Drug; Ethano | 2003 |
Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose.
Topics: Alcohol Drinking; Animals; Baclofen; Central Nervous System Depressants; Conditioning, Operant; Dose | 2003 |
Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Benzoxazines; Cannabinoid Receptor Agonists; Dose-Response Rela | 2004 |
The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat.
Topics: Alcohol Drinking; Animals; Baclofen; Dose-Response Relationship, Drug; GABA Agonists; Male; Naltrexo | 2004 |
Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Drug Therapy, Combination; Male; Naltrexone; Rats | 2005 |
Differential G-protein coupling to GABAB receptor in limbic areas of alcohol-preferring and -nonpreferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Central Nervous System Depressants; Cerebellar Cortex; Ethanol; | 2005 |
Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Central Nervous System Depressants; Conditioning, Operant; Dose | 2005 |
The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Behavior, Animal; Central Nervous System Depressants; Condition | 2006 |
Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations.
Topics: Alcohol Drinking; Animals; Baclofen; Central Nervous System Depressants; Data Interpretation, Statis | 2006 |
Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal.
Topics: Alcohol Drinking; Animals; Anxiety; Baclofen; Body Weight; Central Nervous System Depressants; Diet; | 2007 |
Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Behavior, Addictive; GABA Agonists; Humans; Male; Middle Age | 2007 |
Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats.
Topics: Alcohol Drinking; Animals; Baclofen; Behavior, Animal; Choice Behavior; Cues; Extinction, Psychologi | 2008 |
The effects of the GABA(B) agonist baclofen on the temporal and structural characteristics of ethanol intake.
Topics: Alcohol Drinking; Animals; Baclofen; Drinking; Eating; Ethanol; GABA Agonists; Kinetics; Male; Rats; | 1999 |
Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; Drug Evaluation, | 2000 |
Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Animals; Baclofen; Combined Modality Therapy; Dose-Response Rel | 2000 |
GABAergic involvement in the acquisition of voluntary ethanol intake in laboratory rats.
Topics: Alcohol Drinking; Animals; Baclofen; gamma-Aminobutyric Acid; Injections, Intraperitoneal; Isoxazole | 1992 |
Ethanol-induced changes in chloride flux are mediated by both GABA(A) and GABA(B) receptors.
Topics: Alcohol Drinking; Animals; Baclofen; Bicuculline; Cerebral Cortex; Chloride Channels; Chlorides; Dos | 1991 |